3rd Year MBBS
Infection and Inflammation
Penicillins and Beta-Lactamase Inhibitors
Connect classification, bacterial target, resistance, pharmacokinetics and clinical drug selection in one rapid-revision pathway.
AIM Concept Integration structure follows the supplied KMU-controlled synthesis framework. :contentReference[oaicite:0]{index=0}
1. THE TOPIC IN ONE CONNECTED FLOW
Penicillins are beta-lactam antibiotics that differ in spectrum, beta-lactamase stability and pharmacokinetics but share one central action: inhibition of bacterial cell-wall synthesis. Their clinical usefulness depends on whether the organism is susceptible, whether the drug reaches its PBP target, and whether bacterial resistance mechanisms can inactivate or exclude the antibiotic.
Natural, antistaphylococcal, aminopenicillin or antipseudomonal according to required spectrum.
Adequate exposure allows the intact beta-lactam to reach penicillin-binding proteins.
Transpeptidation and peptidoglycan cross-linking are inhibited.
Autolytic activity plus osmotic stress promote bacterial lysis during active growth.
Beta-lactamase, altered PBPs, reduced penetration or efflux can reduce activity.
A suitable beta-lactamase inhibitor can protect the partner drug when a susceptible enzyme is responsible.
2. KEY CLINICAL CONNECTIONS
Susceptible narrow-spectrum organism → natural penicillin may be sufficient → unnecessary broader exposure can be avoided.
MSSA → common staphylococcal penicillinase present → flucloxacillin, oxacillin or nafcillin resists enzymatic hydrolysis.
Acid stability → oral use: penicillin V and amoxicillin are orally useful, while systemic penicillin G is generally parenteral.
Slow depot absorption → prolonged exposure: benzathine penicillin G lasts much longer than aqueous crystalline penicillin G.
Beta-lactamase production → beta-lactam ring hydrolysis → loss of PBP binding → treatment failure.
Clavulanate, sulbactam or tazobactam → enzyme inhibition → partner beta-lactam remains intact and active.
Time above MIC → greater antibacterial effectiveness because penicillins show predominantly time-dependent killing.
Reduced renal elimination → drug accumulation → increased risk of toxicity, including neurological effects at very high concentrations.
3. AIM HIGH-YIELD INTEGRATION REVIEW
Penicillinase-resistant antistaphylococcal drugs can treat susceptible MSSA, but resistance caused by an altered PBP, as in MRSA, is a different mechanism and is not overcome simply by resisting beta-lactamase.